Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05636618 · ClinicalTrials.gov registry record · Phase 1

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

A Phase 1 study of Pheochromocytoma and Paraganglioma, sponsored by Perspective Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
260
Enrollment target
17
Study locations

NCT05636618 is a Phase 1 study of Pheochromocytoma and Paraganglioma that is actively recruiting participants, run by Perspective Therapeutics. The registered enrollment target is 260 participants, below the 501-participant average among 14 other Pheochromocytoma trials with a reported enrollment target (48% lower). The trial reports 17 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05636618, a Phase 1 study of Pheochromocytoma and Paraganglioma, is actively recruiting participants, sponsored by Perspective Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
260 participants
Enrollment target
17
Study locations

Study Summary

This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

Conditions Studied

Pheochromocytoma Paraganglioma Gastroenteropancreatic Neuroendocrine Tumor Neuroendocrine Tumors Unresectable Neuroendocrine Tumor Metastatic Bronchial Neuroendocrine Tumor

Interventions

  • DRUG [203Pb]VMT-α-NET
  • DRUG [212Pb]VMT-α-NET

Study Locations (17)

Michigan

  • Barbara Ann Karmanos Cancer Institute - Detroit
  • BAMF Health - Grand Rapids
  • Michigan Health Professionals - Troy

Florida

  • Mayo Clinic - Jacksonville
  • Biogenix Molecular - Miami

Illinois

  • The University of Chicago - Chicago

Iowa

  • University of Iowa - Iowa City

Kentucky

  • University of Kentucky - Lexington

Maryland

  • Johns Hopkins - Baltimore

Minnesota

  • Mayo Clinic - Rochester

Missouri

  • Washington University - St Louis

Trial Details

FieldValue
Enrollment Target 260 participants
Start Date 2023-09-27
Est. Completion 2029-12-26
Phase Phase 1

Sponsor

Perspective Therapeutics

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05636618

The ClinicalTrials.gov registry entry for NCT05636618 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 501-participant average among 14 other Pheochromocytoma trials with a reported enrollment target (48% lower). The listed sponsor is Perspective Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Pheochromocytoma appearing as the primary indexed condition, and to 2 interventions - of which [203Pb]VMT-α-NET is the first listed.

NCT05636618 reports 17 study locations spanning 14 distinct geographic areas - top geographies include Michigan, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT05636618 about?

NCT05636618 is a clinical study titled "Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors". This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

What is the current status of trial NCT05636618?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2023-09-27. Estimated completion is 2029-12-26.

What conditions does trial NCT05636618 study?

This clinical trial studies the following conditions: Pheochromocytoma, Paraganglioma, Gastroenteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic.

What interventions are being tested in trial NCT05636618?

The interventions under investigation include: [203Pb]VMT-α-NET (DRUG), [212Pb]VMT-α-NET (DRUG).

Who is sponsoring clinical trial NCT05636618?

This trial is sponsored by Perspective Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05636618 being conducted?

This trial has 17 study locations across Florida, Illinois, Iowa, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pheochromocytoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pheochromocytoma

All registered trials for this condition

Paraganglioma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.